Filing Details
- Accession Number:
- 0001209191-20-016348
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-04 18:53:03
- Reporting Period:
- 2020-03-02
- Accepted Time:
- 2020-03-04 18:53:03
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1178879 | Amicus Therapeutics Inc. | FOLD | Pharmaceutical Preparations (2834) | 200422823 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1400971 | L Bradley Campbell | C/O Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury NJ 08512 | Chief Operating Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-03-02 | 7,500 | $5.96 | 370,517 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-03-02 | 15,003 | $9.09 | 355,514 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options (right to buy) | Disposition | 2020-03-02 | 7,500 | $0.00 | 7,500 | $5.96 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
2,500 | 2021-01-19 | No | 4 | M | Direct |
Footnotes
- The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $8.79 to $9.33 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- All of the options were fully vested and exercisable as of March 2, 2020.